<p>enGene Holdings Inc.（纳斯达克代码：ENGN - 获取免费报告）在周三的交易中交易量强劲。交易期间共成交 194,725 股，较前一交易日的 168,385 股增加了 16%。该股最后交易价格为 9.09 美元，之前收盘价为 8.38 美元。</p>
<h2>分析师设定新目标价</h2>
<p>多家研究机构最近对 ENGN 进行了评估。瑞银集团将 enGene 的目标价从 4.00 美元上调至 10.00 美元，并在 11 月 12 日的研究报告中给予该股 “中性” 评级。Citizens Jmp 将 enGene 的目标价从 18.00 美元上调至 21.00 美元，并在 11 月 12 日的研究报告中给予该股 “市场表现优于大盘” 评级。Raymond James Financial 将 enGene 的评级从 “表现优于大盘” 上调至 “强力买入”，并在 11 月 11 日的研究报告中设定 27.00 美元的目标价。Weiss Ratings 在周五的研究报告中重申了对 enGene 的 “卖出（d-）” 评级。最后，花旗集团在 1 月 5 日的研究报告中重申了对 enGene 的 “市场表现优于大盘” 评级。一位投资分析师给予该股 “强力买入” 评级，七位分析师给予 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该股目前的平均评级为 “适度买入”，共识目标价为 22.38 美元。</p>
<p><strong>阅读我们关于 enGene 的最新研究报告</strong></p>
<h2>enGene 价格表现</h2>
<p>该公司 50 日简单移动平均线为 8.16 美元，200 日简单移动平均线为 6.42 美元。公司的流动比率为 6.30，速动比率为 6.30，债务与股本比率为 0.09。该公司的市值为 6.0425 亿美元，市盈率为-3.99，贝塔值为-0.29。</p>
<p>enGene（纳斯达克代码：ENGN - 获取免费报告）最近于 12 月 22 日发布了季度财报。公司报告每股收益（EPS）为（0.73 美元），低于市场共识预期的（0.55 美元）0.18 美元。分析师预计，enGene Holdings Inc.在当前年度将发布-1.56 的每股收益。</p>
<h2>对 enGene 的对冲基金看法</h2>
<p>几家机构投资者和对冲基金最近调整了对 ENGN 的持股。Cresset Asset Management LLC 在第二季度收购了 enGene 的新股份，价值约 36,000 美元。Paloma Partners Management Co 在第二季度收购了 enGene 的新股份，价值约 38,000 美元。PFS Partners LLC 在第三季度购买了 enGene 的新股份，价值约 61,000 美元。Raymond James Financial Inc.在第三季度将其在 enGene 的持股增加了 383.6%。Raymond James Financial Inc.现在拥有该公司 10,000 股股票，价值 68,000 美元，此前在上一季度又购买了 7,932 股。最后，Hudson Bay Capital Management LP 在第三季度收购了 enGene 的新股份，价值 76,000 美元。机构投资者和对冲基金持有该公司 64.16% 的股份。</p>
<h2>关于 enGene</h2>
<p>（获取免费报告）</p>
<p>enGene, Inc 是一家临床阶段的生物制药公司，专注于开发基于基因的肿瘤治疗药物。公司的核心技术是 EnGene 递送载体（EDV）平台，该平台利用非活性、细菌衍生的微细胞直接将治疗药物输送到肿瘤细胞。通过将靶向递送与强效药物结合，enGene 旨在提高癌症治疗的精准性和有效性，同时减少非靶向毒性。</p>
<p>通过其 EDV 平台，enGene 已将多个治疗候选药物推进到临床前和临床阶段。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票，胜过 enGene</li>
<li>将这些代码输入您的普通经纪账户</li>
<li>请勿删除，立即阅读</li>
<li>超过 200 万盎司的定义 - 他们的故事仍在早期</li>
<li>如果您在美国银行账户中存放现金……请立即阅读</li>
<li>什么费用可以从资本利得税中扣除？</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元在 enGene 吗？</h2>
<p>在您考虑 enGene 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在购买，以便在更广泛的市场注意到之前……而 enGene 并不在名单上。</p>
<p>虽然 enGene 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

ENGN

<p>enGene Holdings Inc.（纳斯达克代码：ENGN）交易量增加了 16%，成交 194,725 股。股价从 8.38 美元上涨至 9.09 美元。分析师们设定了新的价格目标，瑞银将其目标从 4.00 美元上调至 10.00 美元，Citizens Jmp 将其目标从 18.00 美元上调至 21.00 美元。Raymond James 将该股票评级上调至 “强力买入”，目标价为 27.00 美元。平均评级为 “适度买入”，共识目标为 22.38 美元。enGene 专注于肿瘤学的基因治疗，利用其 EDV 平台进行靶向递送</p>

<p>enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) saw strong trading volume on Wednesday . 194,725 shares traded hands during trading, an increase of 16% from the previous session's volume of 168,385 shares.The stock last traded at $9.09 and had previously closed at $8.38.</p>
<div class="lb-trans"><p>enGene Holdings Inc.（纳斯达克代码：ENGN - 获取免费报告）在周三的交易中交易量强劲。交易期间共成交 194,725 股，较前一交易日的 168,385 股增加了 16%。该股最后交易价格为 9.09 美元，之前收盘价为 8.38 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>A number of research firms have recently weighed in on ENGN. UBS Group upped their target price on shares of enGene from $4.00 to $10.00 and gave the stock a &#34;neutral&#34; rating in a research report on Wednesday, November 12th. Citizens Jmp boosted their target price on enGene from $18.00 to $21.00 and gave the stock a &#34;market outperform&#34; rating in a research report on Wednesday, November 12th. Raymond James Financial upgraded enGene from an &#34;outperform&#34; rating to a &#34;strong-buy&#34; rating and set a $27.00 price target on the stock in a research note on Tuesday, November 11th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of enGene in a research note on Friday. Finally, Citigroup reaffirmed a &#34;market outperform&#34; rating on shares of enGene in a research report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $22.38.</p>
<div class="lb-trans"><p>多家研究机构最近对 ENGN 进行了评估。瑞银集团将 enGene 的目标价从 4.00 美元上调至 10.00 美元，并在 11 月 12 日的研究报告中给予该股 “中性” 评级。Citizens Jmp 将 enGene 的目标价从 18.00 美元上调至 21.00 美元，并在 11 月 12 日的研究报告中给予该股 “市场表现优于大盘” 评级。Raymond James Financial 将 enGene 的评级从 “表现优于大盘” 上调至 “强力买入”，并在 11 月 11 日的研究报告中设定 27.00 美元的目标价。Weiss Ratings 在周五的研究报告中重申了对 enGene 的 “卖出（d-）” 评级。最后，花旗集团在 1 月 5 日的研究报告中重申了对 enGene 的 “市场表现优于大盘” 评级。一位投资分析师给予该股 “强力买入” 评级，七位分析师给予 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该股目前的平均评级为 “适度买入”，共识目标价为 22.38 美元。</p>
</div><p><strong>Read Our Latest Research Report on enGene</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 enGene 的最新研究报告</strong></p>
</div><h2>enGene Price Performance</h2>
<div class="lb-trans"><h2>enGene 价格表现</h2>
</div><p>The firm has a 50-day simple moving average of $8.16 and a 200-day simple moving average of $6.42. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.09. The firm has a market cap of $604.25 million, a P/E ratio of -3.99 and a beta of -0.29.</p>
<div class="lb-trans"><p>该公司 50 日简单移动平均线为 8.16 美元，200 日简单移动平均线为 6.42 美元。公司的流动比率为 6.30，速动比率为 6.30，债务与股本比率为 0.09。该公司的市值为 6.0425 亿美元，市盈率为-3.99，贝塔值为-0.29。</p>
</div><p>enGene (NASDAQ:ENGN - Get Free Report) last released its quarterly earnings results on Monday, December 22nd. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.18). As a group, analysts forecast that enGene Holdings Inc. will post -1.56 EPS for the current year.</p>
<div class="lb-trans"><p>enGene（纳斯达克代码：ENGN - 获取免费报告）最近于 12 月 22 日发布了季度财报。公司报告每股收益（EPS）为（0.73 美元），低于市场共识预期的（0.55 美元）0.18 美元。分析师预计，enGene Holdings Inc.在当前年度将发布-1.56 的每股收益。</p>
</div><h2>Hedge Funds Weigh In On enGene</h2>
<div class="lb-trans"><h2>对 enGene 的对冲基金看法</h2>
</div><p>Several institutional investors and hedge funds have recently modified their holdings of ENGN. Cresset Asset Management LLC acquired a new stake in enGene during the second quarter worth about $36,000. Paloma Partners Management Co acquired a new stake in shares of enGene during the 2nd quarter worth approximately $38,000. PFS Partners LLC purchased a new position in shares of enGene during the 3rd quarter valued at approximately $61,000. Raymond James Financial Inc. increased its holdings in shares of enGene by 383.6% during the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company's stock valued at $68,000 after purchasing an additional 7,932 shares in the last quarter. Finally, Hudson Bay Capital Management LP acquired a new position in shares of enGene in the 3rd quarter valued at $76,000. Institutional investors and hedge funds own 64.16% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近调整了对 ENGN 的持股。Cresset Asset Management LLC 在第二季度收购了 enGene 的新股份，价值约 36,000 美元。Paloma Partners Management Co 在第二季度收购了 enGene 的新股份，价值约 38,000 美元。PFS Partners LLC 在第三季度购买了 enGene 的新股份，价值约 61,000 美元。Raymond James Financial Inc.在第三季度将其在 enGene 的持股增加了 383.6%。Raymond James Financial Inc.现在拥有该公司 10,000 股股票，价值 68,000 美元，此前在上一季度又购买了 7,932 股。最后，Hudson Bay Capital Management LP 在第三季度收购了 enGene 的新股份，价值 76,000 美元。机构投资者和对冲基金持有该公司 64.16% 的股份。</p>
</div><h2>About enGene</h2>
<div class="lb-trans"><h2>关于 enGene</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.</p>
<div class="lb-trans"><p>enGene, Inc 是一家临床阶段的生物制药公司，专注于开发基于基因的肿瘤治疗药物。公司的核心技术是 EnGene 递送载体（EDV）平台，该平台利用非活性、细菌衍生的微细胞直接将治疗药物输送到肿瘤细胞。通过将靶向递送与强效药物结合，enGene 旨在提高癌症治疗的精准性和有效性，同时减少非靶向毒性。</p>
</div><p>Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.</p>
<div class="lb-trans"><p>通过其 EDV 平台，enGene 已将多个治疗候选药物推进到临床前和临床阶段。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than enGene</li>
<li>Punch these codes into your ordinary brokerage account</li>
<li>Do not delete, read immediately</li>
<li>More than 2 million ounces defined - and still early in their story</li>
<li>If You Keep Cash In A U.S. Bank Account… Read This NOW</li>
<li>What Expenses Can Be Deducted From Capital Gains Tax?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 enGene</li>
<li>将这些代码输入您的普通经纪账户</li>
<li>请勿删除，立即阅读</li>
<li>超过 200 万盎司的定义 - 他们的故事仍在早期</li>
<li>如果您在美国银行账户中存放现金……请立即阅读</li>
<li>什么费用可以从资本利得税中扣除？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in enGene Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 enGene 吗？</h2>
</div><p>Before you consider enGene, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 enGene 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and enGene wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在购买，以便在更广泛的市场注意到之前……而 enGene 并不在名单上。</p>
</div><p>While enGene currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 enGene 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

enGene（NASDAQ:ENGN）交易量大幅增加 - 仍然值得购买吗？